Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
BioLineRx. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
BioLineRx's earnings available for a low price, and how does
this compare to other companies in the same industry?
BioLineRx's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if BioLineRx is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
BioLineRx's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLineRx, Ltd. from May 24, 2009 to October 10, 2016 and also served as its Principal Accounting Officer until October 10, 2016. Mr. Serlin served as the Chief Financial Officer and Chief Operating Officer of Kayote Networks, Inc from January 2008 to August 2008. He served as Vice President of Finance at TesCom Software Systems Testing Ltd. from January 2006 to December 31, 2007 and served as its Chief Financial Officer from January 2006 to December 2007. Mr. Serlin joined Tescom from Chiaro Networks Ltd., where he served as Corporate Controller and Finance Manager since 2000 and also served as its Vice President of Finance. From January 2000 to December 2005, he served as Chief Accounting Officer for Chiaro Networks Ltd. He has over 25 years of experience in accounting and finance. He has extensive experience of financial reporting and regulatory affairs. From June 1986 to December 1992, he served as senior accountant/analyst and Technical Accounting Advisor/Investigator at the US Securities and Exchange Commission. He served in a number of senior managerial roles at leading Israeli companies. From January 1994 to December 1999, he served as Senior Manager at Deloitte Touche Tohmatsu (Brightman, Almagor & Co), where he headed the SEC and U.S. accounting department at the Tel Aviv national office. He served senior financial positions with other publicly traded companies, as well as at Deloitte and the Securities and Exchange Commission (SEC). He served as an Independent Director of Vascular Biogenics Ltd. since February 11, 2015 until June 7, 2018. He served as a Director of Vringo, Inc. from May 2010 to July 19, 2012. He served as Director of Kitov Pharmaceuticals Holdings Ltd. since July 2013 until March 2016. He is a Certified Public Accountant. Mr. Serlin is a Member of the American Institute of Certified Public Accountants and holds a Master of Business Administration from the George Washington University, USA. He holds a Master's degree in Economics and Public Policy from The George Washington University. Mr. Serlin holds a BS Degree in Accounting from Yeshiva University.
Phil's compensation has increased whilst company is loss making.
Phil's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the BioLineRx management team is about average.
Chief Executive Officer
Chief Financial Officer
Vice President Research & Development
Vice President of Clinical Development
Internal Enforcement Officer
Budget Control Manager and Treasurer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the BioLineRx board of directors is about average.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech’s Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is based in Modi’in, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.